Pure Play vs. Diversification
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
Address: Department for Business, Innovation & Skills, 1 Victoria Street, London SW1H 0ET, United Kingdom
Tel: +44 (0)20 7215 5000
Web: https://www.gov.uk/government/organisations/department-for-business-innovation-skills
The Department for Business, Innovation and Skills (BIS) is building a dynamic and competitive UK economy by: creating the conditions for business success; promoting innovation, enterprise and science; and giving everyone the skills and opportunities to succeed. To achieve this it will foster world-class universities and promote an open global economy. BIS – Investing in our future
The Department for Business, Innovation and Skills (BIS) has an important role at the heart of government as the ‘department for growth’.
That’s why BIS is leading work across government to develop a more balanced and sustainable model for growth. We are building on the Strategy for Sustainable Growth, published in July, with a view to publishing a White Paper in the autumn.
British business can’t prosper while the risk of a debt crisis hangs over the economy. Striking the right balance between making savings and promoting sustainable growth is crucial. This is not just about cuts, but about creating a stable environment that enables businesses to invest and grow with confidence.
We aim to create an enterprise culture where everyone with talent is inspired to turn ideas into successful enterprises and get rid of unnecessary barriers that can stifle growth.
There are three key ways BIS is contributing:
x promoting business and innovation;
x creating a highly-skilled workforce and;
x promoting free and open markets.
The Government, led by BIS, wants to rebalance the economy. This means moving away from an economy reliant on debt to a sustainable one that is greener and more technologically advanced. And it means creating opportunities which are spread more across the regions, and through those sectors where the UK is strong and can add real value.
In a world where there is less money, the role of the state needs to change to get a smarter balance of public and private investment in the economy. We will refocus public spending on those areas where it has the greatest impact on growth and make sure that wider Government policy protects and supports the business environment.
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing approximately 650 people in…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
See our Cookie Privacy Policy Here
